NCT00865852View on ClinicalTrials.gov

A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Non-fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

August 31, 2003

Study Completion Date

August 31, 2003

Conditions
Healthy
Interventions
DRUG

Metformin HCl 750 mg Extender Release tablets, single dose

A: Experimental Subjects received Purepac formulated products under non-fasting conditions

DRUG

GLUCOPHAGE® XR 750 mg tablets, single dose

B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions

Trial Locations (1)

58102

PRACS Institute, Ltd., Fargo

Sponsors

Lead Sponsor

Actavis Inc.
All Listed Sponsors
lead

Actavis Inc.

INDUSTRY

NCT00865852 - A Relative Bioavailability Study of Metformin HCl 750 mg ER Tablets Under Non-fasting Conditions | Biotech Hunter | Biotech Hunter